Receptors, Tumor Necrosis Factor

• 

  Subject Areas on Research

  • * CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. 
  • A boy with fever and whorl keratopathy. 
  • A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group. 
  • A crucial role for p80 TNF-R2 in amplifying p60 TNF-R1 apoptosis signals in T lymphocytes. 
  • A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. 
  • A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. 
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. 
  • A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. 
  • A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. 
  • A third distinct tumor necrosis factor receptor of orthopoxviruses. 
  • A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. 
  • Acute pancreatitis induces FasL gene expression and apoptosis in the liver. 
  • Allelic association of sequence variants in the herpes virus entry mediator-B gene (PVRL2) with the severity of multiple sclerosis. 
  • Alternate functions of viral regulators of cell death. 
  • Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin. 
  • Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. 
  • Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). 
  • BLyS and APRIL in rheumatoid arthritis. 
  • Blockade of tissue factor: treatment for organ injury in established sepsis. 
  • CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Cell density-dependent regulation of cell surface expression of two types of human tumor necrosis factor receptors and its effect on cellular response. 
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. 
  • Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. 
  • Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. 
  • Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. 
  • Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. 
  • Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. 
  • Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. 
  • Direct-contact co-culture between smooth muscle and endothelial cells inhibits TNF-alpha-mediated endothelial cell activation. 
  • Discovery of high-affinity peptide binders to BLyS by phage display. 
  • Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. 
  • Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. 
  • Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40. 
  • Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. 
  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. 
  • Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. 
  • Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. 
  • Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signaling using spectral variants of the green fluorescent protein. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. 
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. 
  • IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-alpha. 
  • Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. 
  • Inflammatory biomarkers in heart failure. 
  • Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells. 
  • Juvenile idiopathic arthritis. 
  • Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 
  • Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)-/- mice. 
  • Moderate-intensity aerobic training program improves insulin sensitivity and inflammatory markers in a pilot study of morbidly obese minority teens. 
  • NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. 
  • Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. 
  • New treatments for rheumatoid arthritis. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • On the TRAIL from p53 to apoptosis? 
  • Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). 
  • Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phosphorylation of tumor necrosis factor receptor 1 (p55) protects macrophages from silica-induced apoptosis. 
  • Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. 
  • Photoreceptor synapses degenerate early in experimental choroidal neovascularization. 
  • Poxviral modifiers of cytokine responses to infection. 
  • Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. 
  • Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Proinflammatory cytokines increase in sepsis after anti-adhesion molecule therapy. 
  • Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 
  • Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. 
  • RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. 
  • Receptor-mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: synergistic actions with interferon-gamma and 1,25-dihydroxyvitamin D3. 
  • Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery. 
  • Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. 
  • Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. 
  • Role of Fn14 in acute alcoholic steatohepatitis in mice. 
  • Signaling by the TNF receptor superfamily and T cell homeostasis. 
  • Signaling pathway for apoptosis: a racetrack for life or death. 
  • Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. 
  • Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. 
  • Spatiotemporal programming of a simple inflammatory process. 
  • Spinal injection of TNF-α-activated astrocytes produces persistent pain symptom mechanical allodynia by releasing monocyte chemoattractant protein-1. 
  • Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Suppression of antiproliferative effects of tumor necrosis factor by transfection of cells with human platelet-derived growth factor B/c-sis gene. 
  • TNF-α contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. 
  • TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. 
  • Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. 
  • Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. 
  • The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis. 
  • The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. 
  • The role of apoptosis in the development and function of T lymphocytes. 
  • Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. 
  • Tides of inflammation: impact of biologics. 
  • Transfection of cells with transforming growth factor-alpha leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. 
  • Treatment of juvenile pityriasis rubra pilaris with etanercept. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Tumor necrosis factor alpha (TNF alpha)-induced ICAM-1 surface expression in airway epithelial cells in vitro: possible signal transduction mechanisms. 
  • Tumor necrosis factor alpha and colitis-associated colon cancer. 
  • Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. 
  • Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes. 
  • Tumor necrosis factor blockers in rheumatoid arthritis. 
  • Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 
  • Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. 
  • Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). 
  • pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology